466
Views
36
CrossRef citations to date
0
Altmetric
Review

Update on the treatment of narcolepsy: clinical efficacy of pitolisant

Pages 127-133 | Published online: 26 Apr 2017

References

  • BlackSWYamanakaAKilduffTSChallenges in the development of therapeutics for narcolepsyProg Neurobiol Epub2015122325784645
  • BassettiCAldrichMSNarcolepsyNeurol Clin19961435455718871976
  • BoganRSwickTMamelakMEvaluation of quality of life in patients with narcolepsy treated with sodium oxybate: use of the 36-item short-form health survey in a clinical trialNeurol Ther20165220321327778193
  • SwickTJTreatment paradigms for cataplexy in narcolepsy: past, present, and futureNat Sci Sleep2015715916926715865
  • NishinoSSakuraiENevsimalovaSDecreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controlsSleep200932217518019238804
  • LongstrethWTJrKoepsellTDTonTGHendricksonAFvan BelleGThe epidemiology of narcolepsySleep2007301132617310860
  • MaskiKUnderstanding racial differences in narcolepsy symptoms may improve diagnosisSleep201538111663166426446120
  • AhmedSSMontomoliEPasiniFLSteinmanLThe safety of adjuvanted vaccines revisited: vaccine-induced narcolepsyIsr Med Assoc J2016183–421622027228647
  • KamalRMvan NoordenMSFranzekEDijkstraBALoonenAJDe JongCAThe neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: a reviewNeuropsychobiology2016732658027003176
  • ThorpyMJDauvilliersYClinical and practical considerations in the pharmacologic management of narcolepsySleep Med201516191825458251
  • SundvikMPanulaPInteractions of the orexin/hypocretin neurons and the histaminergic systemActa Physiol (Oxf)2015213232133325484194
  • HaasHLSergeevaOASelbachOHistamine in the nervous systemPhysiol Rev20088831183124118626069
  • De la Herran-AritaAKGarcia-GarciaFCurrent and emerging options for the drug treatment of narcolepsyDrugs201373161771178124122734
  • ParmentierRAnacletCGuhennecCThe brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disordersBiochem Pharmacol20077381157117117288995
  • SchwartzJCLecomteJMClinical trials with H3-receptor inverse agonists: what they tell us about the role of histamine in the human brainNeuropharmacology2016106353627060410
  • SyedYYPitolisant: first global approvalDrugs201676131313131827438291
  • European Medicines AgencyWakix (Pitolisant): Summary of Product Charatcteristics2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002616/WC500204746.pdfAccessed January 4, 2017
  • BialerMJohannessenSILevyRHPeruccaETomsonTWhiteHSProgress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII)Epilepsy Res20151118514125769377
  • LinJSDauvilliersYArnulfIAn inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patientsNeurobiol Dis2008301748318295497
  • DauvilliersYBassettiCLammersGJPitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trialLancet Neurol201312111068107524107292
  • SzakacsZDauvilliersYMikhaylovVSafety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trialLancet Neurol201716320020728129985
  • InocenteCArnulfIBastujiHPitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepinessClin Neuropharmacol2012352556022356925
  • MitlerMMGujavartyKSBrowmanCPMaintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolenceElectroencephalogr Clin Neurophysiol19825366586616177511
  • van der HeideAvan SchieMKLammersGJComparing treatment effect measurements in narcolepsy: the sustained attention to response task, Epworth Sleepiness Scale and maintenance of wakefulness testSleep20153871051105825902810
  • TanejaASahariaPChadhaNRajputAGoelAA network meta-analysis on comparative efficacy and safety of investigational and approved therapies for the treatment of narcolepsyValue Health2016193A60
  • DauvilliersYArnulfISzakacsZLong term use of pitolisant to treat narcolepsy: HARMONY III studyJ Sleep Res201625275
  • HidalgoHMayerGGeislerPYoungPKallweitUPitolisant as therapeutic option for narcolepsy: results from the German compassionate-program 2015/16J Sleep Res201625366
  • GemkowMJDavenportAJHarichSEllenbroekBACesuraAHallettDThe histamine H3 receptor as a therapeutic drug target for CNS disordersDrug Discov Today2009149–1050951519429511